|
|
|
|
|
Amsacrine
drug data and news
Amsacrine drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Amsacrine | ||
| Brand Names/Synonyms | AMSA P-D; Acridinyl Anisidide; Amsacrine; Amsidine; Amsidyl; Amsine; M-Amsa; Mamsa | ||
| Indication | For treatment of acute myeloid leukaemia. | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Amsacrine is an acridine dye derivative that was synthesized in New Zealand in 1974. It entered clinical trials in 1977. Amsacrine is a DNA-reactive or DNA interchelating agent. It is indicated for induction of remission in acute adult leukemia refractory to conventional therapy. | ||
| Mechanism Of Action | Amsacrine binds to DNA through intercalation and external binding. It has a base specificity for A-T pairs. Rapidly dividing cells are two to four times more sensitive to amsacrine than are resting cells. Amsacrine appears to cleave DNA by inducing double stranded breaks. Amsacrine also targets and inhibits topoisomerase II. Cytotoxicity is greatest during the S phase of the cell cycle when topoisomerase levels are at a maximum. | ||
| Amsacrine News (When available) |
| ||
| Dosage Forms | LIQUID | ||
| Drug_Category | Antineoplastic Agents; ATC:L01XX01 | ||
| Absorption | poorly absorbed | ||
| Interactions | Not Available | ||
| Toxicity | nausea and vomiting, diarrhea, some cardiotoxicity (rarely) | ||
| Organisms Affected | Humans and other mammals | ||
| Chemical IUPAC Name | N-(4-acridin-9-ylamino-3-methoxy-phenyl)methanesulfonamide | ||
| Chemical Formula | C21H19N3O3S | ||
| Molecular Weight | 393.46 g/mol | ||
| Smiles String | COC1=C(C=CC(=C1)NS(=O)(=O)C)NC2=C3C=CC=CC3=NC4=CC=CC=C42 | ||
| Melting Point | Not Available | ||
| Water Solubility | <1 mg/mL | ||
| State | Solid | ||
| LogP/Hphobicity | 5.273 | ||
| Isoelectric Point | Not Available | ||
| Biotransformation | primarily hepatic, converted to glutathione conjugate | ||
| Half Life | 8-9 hours | ||
| Protein Binding [%] | 96%-98% | ||
| RxList Link | Not Available>RXlist | ||
| Sponsored links | |||
| Drug Reference |
http://www.drugs.com/cons/Amsacrine.html http://www.bccancer.bc.ca/HPI/DrugDatabase/DrugIndexPro/Amsacrine.htm | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00064 | ||
| CAS Registry Number | 51264-14-3 | ||
| KEGG Compound ID | C01553 | ||
| PubChem ID | SID:4711 | ||
| PharmGKB ID | PA10309 | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | 582212 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |